Why the study?
Does telmisartan or the combination of telmisartan and ramipril improve outcomes compared to ramipril in patients with vascular disease or high-risk diabetes?
Does telmisartan or the combination of telmisartan and ramipril improve outcomes compared to ramipril in patients with vascular disease or high-risk diabetes?
Telmisartan is an effective alternative to ramipril with a lower risk of angioedema in high-risk vascular patients, but combining the two agents increases adverse events without added benefit.
Answers are grounded in this paper and cite their sources.
Telmisartan is a suitable ramipril alternative with less angioedema; confirms no benefit and more harm from dual blockade in high-risk patients.
Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
The ONTARGET Investigators (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: